Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Microphyt has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The company's current prosecution activity is focused on this single matter. Practitioners should observe that the active portfolio in this sector is currently subject to the review of this administrative division, which defines the communication chain for the prosecution outcome.
The busiest examiner is YOUNGBLOOD, WILLIAM JUSTIN, who holds 1 busiest_examiner_pending action. This examiner is the only one currently reviewing the company's pending applications. Because there is 1 pending office action total, the outcome of the current prosecution relates to the perspective and interpretation of this individual. The involvement of 1 distinct art unit further defines this prosecution environment, requiring a strategy that addresses the precedents and guidelines of that unit. Success in this matter will depend on addressing the concerns of this 1 distinct examiner within the framework of their assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718170 | Composition and application, in particular cosmetic | YOUNGBLOOD, WILLIAM JUSTIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718170 | Composition and application, in particular cosmetic | YOUNGBLOOD, WILLIAM JUSTIN | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18718170 | Composition and application, in particular cosmetic | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102§112 | Non-Final OA | — | Pending | Jun 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMicrophyt has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William Justin Youngblood has the most, with 1 of Microphyt's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
